IntelliProve is a technology company.
IntelliProve has raised $1.0M across 1 funding round.
IntelliProve has raised $1.0M in total across 1 funding round.
IntelliProve is a Belgium-based digital healthcare startup founded in 2021 that develops a plug-in software tool using facial analysis technology to provide clinically-validated biomarker data from short smartphone videos.[1][2][3][5] The product integrates seamlessly into existing digital health, wellbeing, and employee platforms, serving sectors like corporate wellbeing, health insurance, and mental health solutions by enabling hyper-personalized health journeys, proactive monitoring, and increased user engagement—such as a reported 20% boost within three months.[1][3][5] It solves the problem of accessible, contactless health assessments without hardware, targeting health providers, insurers (e.g., Helan, Neutraal Ziekenfonds Vlaanderen), and wellbeing apps across seven European countries, with 2024 revenue tripling and $2.34M raised in seed funding.[1]
IntelliProve was founded in 2021 in Destelbergen, Belgium, by Maxime Mattelin (CEO), Tanguy Sanglet (COO), Brecht Dhuyvetters (CPO), and Joeri Tulkens (CTO), who leveraged expertise in signal processing, computer vision, and health tech to create smartphone-based "digital biopsies" for vital parameters like blood flow and wellbeing indicators.[1][4] The idea emerged from combining AI, machine learning, and optical face measurements to deliver fast, accurate health data, gaining early traction through partnerships with Het Wit-Gele Kruis, TU Delft, vzw Zorg-Saam, and imec.istart, alongside seed funding from imec.istart fund, The White and Yellow Cross, and business angels.[1] A pivotal €1M raise about four months ago fueled expansion, marking operational growth into multiple European markets.[1][2]
IntelliProve rides the wave of AI-driven preventive healthcare and digital biomarkers, capitalizing on post-pandemic demand for remote, accessible monitoring amid rising mental health and corporate wellbeing needs.[1][3][5] Timing aligns with Europe's health tech boom, where contactless tools address scalability issues in traditional assessments, fueled by market forces like aging populations, employee retention pressures, and AI advancements in computer vision.[1][2] It influences the ecosystem by partnering with incumbents (e.g., insurers, research institutes), enhancing platforms' competitiveness, and promoting "digital biopsies" to shift healthcare from reactive to proactive, particularly in fragmented EU wellbeing markets.[1][3]
IntelliProve is poised for accelerated expansion with recent funding, likely deepening EU penetration and piloting in new verticals like telehealth amid AI health tech's projected growth.[1][2] Trends like multimodal AI biomarkers and regulatory tailwinds for digital health will shape its path, potentially evolving from plug-in provider to full-stack platform influencer. As it scales from seed-stage momentum, IntelliProve exemplifies how facial analysis tech transforms everyday devices into life-saving tools, tying back to its mission of revolutionizing health monitoring one biomarker at a time.[4][5]
IntelliProve has raised $1.0M in total across 1 funding round.
IntelliProve's investors include Pitchdrive, Boris Bogaert, Pieterjan Bouten, Toon Coppens.
IntelliProve has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $1.0M Seed | Pitchdrive, Boris Bogaert, Pieterjan Bouten, Toon Coppens |